Species-specific Inflammatory Responses as a Primary Component for the Development of Glomerular Lesions in Mice and Monkeys Following Chronic Administration of a Second-generation Antisense Oligonucleotide

Toxicologic Pathology

Volumn 42, Issue 5, 2014, Pages 923-935

  Frazier, Kendall S ^a   Sobry, Cécile ^b   Derr, Victoria ^c   Adams, Mike J ^d   Besten, Cathaline Den ^e   Kimpe, Sjef de ^e   Francis, Ian ^d   Gales, Tracy L ^a   Haworth, Richard ^d   Maguire, Shaun R ^d   Mirabile, Rosanna C ^a   Mullins, David ^a   Palate, Bernard ^b   Doorten, Yolanda Ponstein Simarro ^e   Ridings, James E ^d   Scicchitano, Marshall S ^a   Silvano, Jérémy ^b   Woodfine, Jennie ^d  

^a GLAXOSMITHKLINE   (United States)

^b SOLVO BIOTECHNOLOGY   (Hungary)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e Prosensa Therapeutics   (Netherlands)

Author keywords

amyloid; glomerulonephritis; hyaline glomerulopathy; monkey pathology; mouse pathology; renal; safety assessment

Indexed keywords

CD68 ANTIGEN; DRISAPERSEN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; ANTISENSE OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPERIMENTAL MONKEY; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY CORTEX; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY PAPILLA NECROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; GLOMERULUS; HAPLORHINI; KIDNEY DISEASE; PATHOLOGY; RISK ASSESSMENT; SPECIES DIFFERENCE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HAPLORHINI; INFLAMMATION; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; OLIGONUCLEOTIDES, ANTISENSE; RISK ASSESSMENT; SPECIES SPECIFICITY;

EID: 84903639158     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623313505781     Document Type: Article

References (24)

1. Barbour T. D. Pickering M. C. Cook H. T. (2013). Recent insights into C3 glomerulopathy. Nephrol Dial Transplant 0, 1−8. doi:10.1093/ndt/gfs430.
2. Dalmas D. A. Scicchitano M. S. Chen Y. Kane J. Mirabile R. Schwartz L. W. Thomas H. C. Boyce R. W. (2008). Profiling of laser capture microdissected rat arterial elements: Fenoldopam-induced vascular toxicity as a model system. Toxicol Pathol 36, 496−519.
3. Dalmas D. A. Zimmerman D. Scicchitano M. S. Tierney L. A. Boyce R. W. (2005). Target gene localization using laser capture microdissection and real-time RT-PCR analysis. J Histotechnol 28, 177−80.
4. Faccini J. M. Abbot D. P. Paulus J. J. (1990). Mouse Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies, pp. 75–220. Amsterdam, Elsevier.
5. Frazier K. S. Seely J. C. (2013). Urinary system. In Toxicologic Pathology: Preclinical Safety Assessment (Sahota P. S. Popp J. A. Hardisty J. F. Gopinath C., eds.), pp. 421−84. CRC Press/Taylor Francis Pub., Boca Raton, FL
6. Frazier K. S. Seely J. C. Hard G. C. Betton G. C. Burnett R. Nishikawa A. Nakatsuji S. Durchfeld-Meyer B. Bube A. (2012). Proliferative and nonproliferative lesions in the rodent urinary system. Toxicol Pathol 40, 14−86.
7. Gise H. Christ H. Bohle A. (1981). Early glomerular lesions in amyloidosis. Virchows Arch (A) 390, 259−72.
8. Henry S. P. Giclas P. C. Leeds J. Pangburn M. Auletta C. Levin A. A. Kornbust D. J. (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J Pharmacol Exp Ther 281, 810−6.
9. Henry S. P. Kim T.-W. Kramer-Stickland K. Zanardi T. A. Fey R. A. Levin A. A. (2008). Toxicologic properties of 2′-methoxyethyl chimeric antisense inhibitors in animals and man. In Antisense Drug Technology: Principles, Strategies and Applications (Crooke S. T., ed.), 2nd ed., pp. 327−63. CRC Press, Carlsbad, CA.
10. Henry S. P. Templin M. V. Gillett N. Rojko J. Levin A. A. (1999). Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol 27, 95−100.
11. Jones B. Thorner P. Singh A. Patterson J. Lumsden J. Valli V. Baumal R. Basrur P. (1984). Animal models of human disease: Hereditary nephritis in samoyed dogs. Am J Pathol 116, 175−8.
12. Krieg A. M. (1998). Leukocyte stimulation by oligodeoxynucleotides. In Applied Antisense Oligonucleotide Technology (Stein C. A. Krieg A. M., eds.), pp. 431−48. Wiley-Liss, New York, NY.
13. Kwoh T. J. (2007). An overview of the clinical safety experience of first and second generation antisense oligonucleotides. In Antisense Drug Technology (Crooke S. T., ed.), 2nd ed., pp. 365−400. Taylor and Francis, Boca Raton.
14. Linder E. Pasternack A. Edgington T. S. (1972.) Pathology and immunology of age-associated disease of mice and evidence for an autologous immune complex pathogenesis of the associated renal disease. Clin Immunol Immunopathol 1, 104−21.
15. Marquis J. K. Grindel J. M. (2000). Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther 2, 258−63.
16. Monteith D. K. Horner M. J. Gillett N. A. Butler M. Geary R. Burckin T. Ushiro-Watanabe T. Levin A. (1999). Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol 27, 307−17.
17. Monteith D. K. Levin A. A. (1999). Synthetic oligonucleotides: The development of antisense therapeutics. Toxicol Pathol 27, 8−13.
18. Pickering T. D. Cook M. C. (2008). Translational mini-review series on complement factor H: Renal diseases associated with complement factor H: Novel insights from humans and animals. Clinl Exp Immunol 151, 210–30.
19. Rao S. Watkins D. Cunningham D. Dunlop D. Johnson P. Selby P. Hancock B. W. Fegan C. Culligan D. Schey S. Morris T. C. M. Lissitchkov T. Oliver J. W. (2004). Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C, in patients with previously treated low-grade non-Hodgkin’s lymphoma. Ann Oncol 15, 1413−8.
20. Richardt-Pargmann D. Vollmer J. (2009). Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors. Ann N Y Acad Sci 1175, 40−54.
21. Sachs S. H. Zhous W. Sheerin N. S. (1996). Complement synthesis in the injured kidney: Does it have a role in immune complex glomerulonephritis? J Am Soc Nephrol 7, 2314−9.
22. Schwartz M. M. (2007a). Membranous glomerulonephritis. In Heptinstall’s Pathology of the Kidney (Jennette J. C. Olson J. L. Schwartz M. M. Silva F. G., eds.), 6th ed., pp. 205−51. Lippincott Williams &Wilkins, Philadelphia.
23. Schwartz M. M. (2007b). Glomerular diseases with organized deposits. In Heptinstall’s Pathology of the Kidney (Jennette J. C. Olson J. L. Schwartz M. M. Silva F. G., eds.), 6th ed., pp. 919−25. Lippincott Williams & Wilkins, Philadelphia.
24. Wojcinski Z. W. Albassam M. A. Smith G. S. (1991). Hyaline glomerulopathy in B6C3F1 mice. Toxicol Pathol 19, 224−9.